This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

QIAGEN Reports Fourth Quarter And Full-Year 2012 Results

VENLO, The Netherlands, January 29, 2013 /PRNewswire/ --
  • QIAGEN exceeds Q4 and full-year 2012 targets:
  • Full-year 2012: Net sales advance 10% CER (+7% reported) to $1.25 billion on growth in all customer classes and regions; adjusted diluted EPS at $1.08 per share
  • Q4 2012: Net sales rise 4% CER (+4% reported) to $346.5 million, year-ago results included major product tender; adjusted diluted EPS at $0.34 per share
  • Building on 2012 progress to accelerate innovation and growth in 2013:
  • Driving platform success: Rapid adoption of QIAsymphony automation platform set to exceed an installed base of 1,000 systems during 2013
  • Sample-to-result next-generation sequencing workflow for clinical research and diagnostics on track for 2013 launch
  • Adding content: Over 35 molecular diagnostic assay projects in pipeline; exceeding targets for conversion to FDA-approved  therascreen    KRAS companion diagnostic
  • Growing efficiently and effectively: Adjusted operating income margin at 28% of net sales for full-year 2012, reaches 31% in Q4 2012
  • QIAGEN expects to deliver higher sales and adjusted earnings in 2013

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the fourth quarter and full-year 2012, delivering growth in net sales and adjusted earnings that exceeded targets, and set new goals for improved sales and adjusted earnings in 2013.

"QIAGEN made significant progress during 2012 on initiatives to drive innovation and growth. These actions fueled demand for our products across all of our customer classes and regions, enabling us to exceed our targets for 2012 and deliver double-digit sales growth at constant exchange rates and adjusted earnings at a faster pace than in 2011," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. "Results for the fourth quarter of 2012 also exceeded our targets, as we delivered solid growth over the year-ago quarter, which included sales from a major product tender."

"Although the business environment remains challenging, our strategy is demonstrating traction and we have set a goal to further improve sales and adjusted earnings in 2013," Mr. Schatz said. "Multiple growth drivers are building momentum as we move into 2013. We intend to add to our leadership in Personalized Healthcare by further expanding our position as the partner of choice for molecular companion diagnostics as well as by building our assay portfolio and driving adoption. Growing placements of our QIAsymphony automation platform are enabling the dissemination of molecular testing, while our QuantiFERON-TB test is improving the standard of care for latent tuberculosis (TB). Innovation goals for 2013 include our entry into targeted areas of next-generation sequencing with workflow solutions for clinical research and human healthcare, as well as advancing our R&D pipeline of more than 35 molecular diagnostic assay projects. We will also step up initiatives to improve efficiency and effectiveness, especially our capabilities to address the needs of customers. We are well-positioned to achieve our goals for 2013 and fulfill our mission of making improvements in life possible."

1 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs